Cost-Effectiveness Analysis of HPV Vaccination: Comparing the General Population with Socially Vulnerable Individuals

  • Han, Kyu-Tae (Department of Public Health, College of Medicine, Yonsei University) ;
  • Kim, Sun Jung (Department of Public Health, College of Medicine, Yonsei University) ;
  • Lee, Seo Yoon (Institute of Health Services Research, College of Medicine, Yonsei University) ;
  • Park, Eun-Cheol (Department of Public Health, College of Medicine, Yonsei University)
  • Published : 2014.10.23


Background: After the WHO recommended HPV vaccination of the general population in 2009, government support of HPV vaccination programs was increased in many countries. However, this policy was not implemented in Korea due to perceived low cost-effectiveness. Thus, the aim of this study was to analyze the cost-utility of HPV vaccination programs targeted to high risk populations as compared to vaccination programs for the general population. Materials and Methods: Each study population was set to 100,000 people in a simulation study to determine the incremental cost-utility ratio (ICUR), then standard prevalence rates, cost, vaccination rates, vaccine efficacy, and the Quality-Adjusted Life-Years (QALYs) were applied to the analysis. In addition, sensitivity analysis was performed by assuming discounted vaccination cost. Results: In the socially vulnerable population, QALYs gained through HPV vaccination were higher than that of the general population (General population: 1,019, Socially vulnerable population: 5,582). The results of ICUR showed that the cost of HPV vaccination was higher for the general population than the socially vulnerable population. (General population: 52,279,255 KRW, Socially vulnerable population: 9,547,347 KRW). Compared with 24 million KRW/QALYs as the social threshold, vaccination of the general population was not cost-effective. In contrast, vaccination of the socially vulnerable population was strongly cost-effective. Conclusions: The results suggest the importance and necessity of government support of HPV vaccination programs targeted to socially vulnerable populations because a targeted approach is much more cost-effective. The implementation of government support for such vaccination programs is a critical strategy for decreasing the burden of HPV infection in Korea.


HPV vaccination;cost-effectiveness analysis;cost-utility analysis;cervical cancer


Supported by : Ministry of Health and Welfare


  1. Aponte-Gonzalez J, Fajardo-Bernal L, Diaz J, et al (2013). Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One, 8, 80639.
  2. da Fonseca AJ, Martin CNR, Gigante RLG, et al (2013). Cost-effectiveness of primary and secondary prevention strategies for cervical cancer in Brazil: a systematic review. Gynecology Obstetrics.
  3. Armstrong EP (2010). Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm, 16, 217-30.
  4. Bambra C (1999). Current status of reproductive behaviour in Africa. Human Reproduction Update, 5, 1-20.
  5. Basu S, Chapman GB, Galvani AP (2008). Integrating epidemiology, psychology, and economics to achieve HPV vaccination targets. Proceedings of the National Academy of Sciences, 105, 19018-23.
  6. Deacon J, Evans C, Yule R, et al (2000). Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer, 83, 1565.
  7. Demarteau N, Tang CH, Chen HC, et al (2012). Costeffectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan. Value Health, 15, 622-31.
  8. Demarteau N, Van Kriekinge G, Simon P (2013). Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre-and post-sexual debut in Belgium. Vaccine, 31, 3962-71.
  9. Do H, Seng P, Talbot J, et al (2009). HPV vaccine knowledge and beliefs among Cambodian American parents and community leaders. Asian Pac J Cancer Prev: APJCP, 10, 339.
  10. Drolet M, Laprise JF, Boily MC, et al (2013). Potential cost effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer, 134, 2264-8.
  11. Dunne EF, Unger ER, Sternberg M, et al (2007). Prevalence of HPV infection among females in the United States. JAMA, 297, 813-9.
  12. Fesenfeld M, Hutubessy R, Jit M (2013). Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine, 31, 3786-804.
  13. Elbasha EH, Dasbach EJ, Insinga RP (2007). Model for assessing human papillomavirus vaccination strategies. Emerging Infect Dis, 13, 28.
  14. Elbasha EH, Dasbach EJ, Insinga RP, et al (2009). Age-based programs for vaccination against HPV. Value Health, 12, 697-707.
  15. English K, Marra F, Davoudi B, et al (2013). O17. 4 evaluating the cost effectiveness of targeted vaccination strategies to reduce incidence of HPV-related cancer and other clinical outcomes in men who have sex with men (MSM) in British Columbia, Canada. Sexually Transmitted Infections, 89, 59-60.
  16. Frohlich KL, Potvin L (2008). Transcending the known in public health practice: the inequality paradox: the population approach and vulnerable populations. Am J Public Health, 98, 216.
  17. Hassan C, Pickhardt P, Laghi A, et al (2008). Computed tomographic colonography to screen for colorectal cancer, extracolonic cancer, and aortic aneurysm: model simulation with cost-effectiveness analysis. Arch Internal Med, 168, 696-705.
  18. Health Insurance Review & Assessment Service (2010-2012). Statistics of disease.
  19. Jeurissen S, Makar A (2009). Epidemiological and economic impact of human papillomavirus vaccines. Int J Gynecological Cancer, 19, 761-71.
  20. Karadag G, Gungormus Z, Surucu R, et al (2014). Awareness and practices regarding breast and cervical cancer among Turkish women in gazientep. Asian Pac J Cancer Prev, 15, 1093.
  21. Kim KH, Kim J-H, Park SE, et al (2007). Human papillomavirus vaccine. Korean J Pediatrics, 50, 811-9.
  22. Mao C, Koutsky LA, Ault KA, et al (2006). Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics & Gynecology, 107, 18-27.
  23. Korea Centers for Disease Control and Prevention (2010-2012). Korea youth risk behavior web-based survey.
  24. Koshiol J, Lindsay L, Pimenta JM, et al (2008). Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol, 168, 123-37.
  25. Liao CH, Liu JT, Pwu RF, et al (2009). Valuation of the economic benefits of human papillomavirus vaccine in Taiwan. Value Health, 12, 74-7.
  26. Marra F, Cloutier K, Oteng B, et al (2009). Effectiveness and cost effectiveness of human papillomavirus vaccine. Pharmacoeconomics, 27, 127-47.
  27. National Evidence-based Healthcare Collaboratiing Agency (2012). Economic evaluation of human papillomavirus vaccination.
  28. Natunen K, Lehtinen T, Torvinen S, Lehtinen M (2013). Costeffectiveness of HPV-vaccination in medium or low income countries with high cervical cancer incidence-a systematic review. J Vaccines Vaccin, 4, 2.
  29. Nyari T, Cseh I, Woodward M, et al (2001). Screening for human papillomavirus infection in asymptomatic women in Hungary. Human Reproduction, 16, 2235-7.
  30. Ozgul N, Tuncer M, Abacioglu M, Gultekin M (2011). Estimating prevalence of genital warts in Turkey: Survey among KETEM-affiliated gynecologists across Turkey. Asian Pac J Cancer Prev, 12, 2397-400.
  31. Shin HR (2007). Burden of human papillomavirus infection related diseases. Korea center for disease control and prevention.
  32. Techakehakij W, Feldman RD (2008). Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine, 26, 6258-65.
  33. The Korea Central Cancer Registry NCC (2010). Annual report of cancer statistics in Korea in 2010. ministry of health and welfare.
  34. Turner HC, Baussano I, Garnett GP (2013). Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. PloS one, 8, 75552.
  35. Villa L, Costa R, Petta C, et al (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer, 95, 1459-66.
  36. WHO (2008). Human papillomavirus (HPV) vaccine background paper.
  37. Wilkinson K (1973). Broken family and juvenile delinquency: scientific explanation or ideology, The Soc Probs, 21, 726.
  38. Woertman W, van der Wilt GJ (2013). Estimating the effectiveness of HPV vaccination in the open population: a Bayesian approach. Value Health, 16, 604-9.
  39. Yilmazel G, Duman NB (2014). Knowledge, attitudes and beliefs about cervical cancer and human papilloma virus vaccination with related factors in Turkish University students. Asian Pac J Cancer Prev, 15, 3699.
  40. Zhang H-Y, Tiggelaar SM, Sahasrabuddhe VV, et al (2012). HPV prevalence and cervical intraepithelial neoplasia among HIVinfected women in Yunnan Province, China: a pilot study. Asian Pac J Cancer Prev, 13, 91.

Cited by

  1. Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea vol.18, pp.1, 2018,